These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23819360)

  • 61. MRI of the Prostate With and Without Endorectal Coil at 3 T: Correlation With Whole-Mount Histopathologic Gleason Score.
    Dhatt R; Choy S; Co SJ; Ischia J; Kozlowski P; Harris AC; Jones EC; Black PC; Goldenberg SL; Chang SD
    AJR Am J Roentgenol; 2020 Jul; 215(1):133-141. PubMed ID: 32160050
    [No Abstract]   [Full Text] [Related]  

  • 62. Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T.
    Koo JH; Kim CK; Choi D; Park BK; Kwon GY; Kim B
    Korean J Radiol; 2013; 14(1):61-9. PubMed ID: 23323032
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy.
    Rosenkrantz AB; Triolo MJ; Melamed J; Rusinek H; Taneja SS; Deng FM
    J Magn Reson Imaging; 2015 Mar; 41(3):708-14. PubMed ID: 24616064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quantitative evaluation of computed high B value diffusion-weighted magnetic resonance imaging of the prostate.
    Maas MC; Fütterer JJ; Scheenen TW
    Invest Radiol; 2013 Nov; 48(11):779-86. PubMed ID: 23907102
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness.
    Tamada T; Kanomata N; Sone T; Jo Y; Miyaji Y; Higashi H; Yamamoto A; Ito K
    PLoS One; 2014; 9(5):e96619. PubMed ID: 24802652
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
    Oto A; Yang C; Kayhan A; Tretiakova M; Antic T; Schmid-Tannwald C; Eggener S; Karczmar GS; Stadler WM
    AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience.
    Park SY; Kim CK; Park JJ; Park BK
    Br J Radiol; 2016; 89(1058):20150470. PubMed ID: 26653866
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
    Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA
    Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Composition-A Hypothesis-generating Study.
    Hectors SJ; Semaan S; Song C; Lewis S; Haines GK; Tewari A; Rastinehad AR; Taouli B
    Radiology; 2018 Mar; 286(3):918-928. PubMed ID: 29117481
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prostate Cancer: Diffusion-weighted MR Imaging for Detection and Assessment of Aggressiveness-Comparison between Conventional and Kurtosis Models.
    Tamada T; Prabhu V; Li J; Babb JS; Taneja SS; Rosenkrantz AB
    Radiology; 2017 Jul; 284(1):100-108. PubMed ID: 28394755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of apparent diffusion coefficient calculation between two-point and multipoint B value analyses in prostate cancer and benign prostate tissue at 3 T: preliminary experience.
    Park SY; Kim CK; Park BK; Kwon GY
    AJR Am J Roentgenol; 2014 Sep; 203(3):W287-94. PubMed ID: 25148186
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MR elastography and diffusion-weighted imaging of ex vivo prostate cancer: quantitative comparison to histopathology.
    Sahebjavaher RS; Nir G; Gagnon LO; Ischia J; Jones EC; Chang SD; Yung A; Honarvar M; Fazli L; Goldenberg SL; Rohling R; Sinkus R; Kozlowski P; Salcudean SE
    NMR Biomed; 2015 Jan; 28(1):89-100. PubMed ID: 25382459
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of apparent diffusion coefficient values in prostate diseases characterization on diffusion-weighted magnetic resonance imaging.
    Salvaggio G; Calamia M; Purpura P; Bartolotta TV; Picone D; Dispensa N; Lunetta C; Bruno A; Raso L; Salvaggio L; Lo Re G; Galia M; Simonato A; Midiri M; Lagalla R
    Minerva Urol Nefrol; 2019 Apr; 71(2):154-160. PubMed ID: 30421590
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.
    Glazer DI; Hassanzadeh E; Fedorov A; Olubiyi OI; Goldberger SS; Penzkofer T; Flood TA; Masry P; Mulkern RV; Hirsch MS; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2017 Mar; 42(3):918-925. PubMed ID: 27770164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers.
    Costa DN; Xi Y; Aziz M; Passoni N; Shakir N; Goldberg K; Francis F; Roehrborn CG; Leon AD; Pedrosa I
    AJR Am J Roentgenol; 2019 Jan; 212(1):109-116. PubMed ID: 30383404
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Everyman's prostate phantom: kiwi-fruit substitute for human prostates at magnetic resonance imaging, diffusion-weighted imaging and magnetic resonance spectroscopy.
    Mueller-Lisse UG; Murer S; Mueller-Lisse UL; Kuhn M; Scheidler J; Scherr M
    Eur Radiol; 2017 Aug; 27(8):3362-3371. PubMed ID: 28058480
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Utility of computed diffusion-weighted MRI for predicting aggressiveness of prostate cancer.
    Waseda Y; Yoshida S; Takahara T; Kwee TC; Matsuoka Y; Saito K; Kihara K; Fujii Y
    J Magn Reson Imaging; 2017 Aug; 46(2):490-496. PubMed ID: 28152258
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Diffusion weighted imaging: its diagnostic and differential value for prostate cancer].
    Shi H; Ding HY
    Zhonghua Nan Ke Xue; 2007 Jul; 13(7):605-9. PubMed ID: 17725302
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Value of diffusion-weighted imaging at 3 T for prediction of extracapsular extension in patients with prostate cancer: a preliminary study.
    Chong Y; Kim CK; Park SY; Park BK; Kwon GY; Park JJ
    AJR Am J Roentgenol; 2014 Apr; 202(4):772-7. PubMed ID: 24660705
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intravoxel Incoherent Motion (IVIM) Diffusion Weighted Imaging (DWI) in the Periferic Prostate Cancer Detection and Stratification.
    Pesapane F; Patella F; Fumarola EM; Panella S; Ierardi AM; Pompili GG; Franceschelli G; Angileri SA; Magenta Biasina A; Carrafiello G
    Med Oncol; 2017 Mar; 34(3):35. PubMed ID: 28144814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.